Pemetrexed: Biochemical and cellular pharmacology, mechanisms, and clinical applications

Molecular Cancer Therapeutics

Volumn 6, Issue 2, 2007, Pages 404-417

  Chattopadhyay, Shrikanta ^a,c   Moran, Richard G ^b   Goldman, I David ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

10 PROPARGYL 5,8 DIDEAZAFOLIC ACID; ACETYLSALICYLIC ACID; AMINOPTERIN; CARBOPLATIN; CARRIER PROTEIN; CISPLATIN; DOCETAXEL; FLUOROURACIL; FOLIC ACID; FOLIC ACID ANTAGONIST; GEMCITABINE; IBUPROFEN; LOMETREXOL; METHOTREXATE; PEMETREXED; PHOSPHORIBOSYLGLYCINAMIDE FORMYLTRANSFERASE; PHOSPHORIBOSYLGLYCINAMIDE FORMYLTRANSFERASE INHIBITOR; POLYGLUTAMIC ACID; PT 632; RALTITREXED; THYMIDYLATE SYNTHASE; UNCLASSIFIED DRUG;

ADD ON THERAPY; ALOPECIA; BONE MARROW TOXICITY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG ACTIVITY; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG FATALITY; DRUG HALF LIFE; DRUG INDICATION; ENZYME INHIBITION; FEBRILE NEUTROPENIA; HUMAN; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; MAXIMUM TOLERATED DOSE; MESOTHELIOMA; MONOTHERAPY; NEPHROTOXICITY; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; RECEPTOR AFFINITY; REVIEW; SIDE EFFECT; VITAMIN SUPPLEMENTATION;

ANTIMETABOLITES, ANTINEOPLASTIC; BIOLOGICAL TRANSPORT; CLINICAL TRIALS; FOLIC ACID; FOLIC ACID ANTAGONISTS; GLUTAMATES; GUANINE; HUMANS; NEOPLASMS;

EID: 33847364471     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-06-0343     Document Type: Review

References (137)

1. Stokstad ELR. Some properties of a growth factor for Lactobacillus casei. J Biol Chem 1943;149:573-4.
2. Hutchings BL, Mowat JH, Oleson JJ, et al. Pteroylaspartic acid, an antagonist for pteroylglutamic acid. J Biol Chem 1947; 170:323-8.
3. Leuchtenberger R, Leuchtenberger C, Laszlo D, Lewisohn R. The influence of "folic acid" on spontaneous breast cancers in mice. Science 1945; 101:46.
4. Farber S, Cutler EC, Hawkins JW, et al. The action of pteroylglutamic conjugates on man. Science 1947; 106:619-21.
5. Farber S, Diamond LK, Mercer RD, Sylvester RF, Wolff VA. Temporary remission in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl glutamic acid (aminopterin). N Engl J Med 1948;238: 787-93.
6. Farber S. Some observations on the effect of folic acid antagonists on acute leukemia and other forms of incurable cancer. Blood 1949;4: 160-7.
7. Werkheiser WC. Specific Binding of 4-amino folic acid analogues by folic acid reductase. J Biol Chem 1961;236:888-93.
8. Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med 2006;354:166-78.
9. Furst DE. The rational use of methotrexate in rheumatoid arthritis and other rheumatic diseases. Br J Rheumatol 1997;36:1196-204.
10. Roenigk HH, Jr., Auerbach R, Maibach H, Weinstein G, Lebwohl M. Methotrexate in psoriasis: consensus conference. J Am Acad Dermatol 1998;38:478-85.
11. Baugh CM, Krumdieck CL, Nair MG. Polygammaglutamyl metabolites of methotrexate. Biochem Biophys Res Commun 1973;52:27-34.
12. Whitehead VM. Synthesis of methotrexate polyglutamates in L1210 murine leukemia cells. Cancer Res 1977;37:408-12.
13. Rosenblatt DS, Whitehead VM, Dupont MM, Vuchich MJ, Vera N. Synthesis of methotrexate polyglutamates in cultured human cells. Mol Pharmacol 1978;14:210-4.
14. Jolivet J, Schilsky RL, Bailey BD, Drake JC, Chabner BA. Synthesis, retention, and biological activity of methotrexate polyglutamates in cultured human breast cancer cells. J Clin Invest 1982;70:351-60.
15. 3-5 to dihydrofolate reductase. J Clin Invest 1983;72:773-8.
16. Fry DW, Yalowich JC, Goldman ID. Rapid formation of poly-gammaglutamyl derivatives of methotrexate and their association with dihydrofolate reductase as assessed by high pressure liquid chromatography in the Ehrlich ascited tumor cell in vitro. J Biol Chem 1982;257:1890-6.
17. Poser RG, Sirotnak FM, Chello PL. Differential synthesis of methotrexate polyglutamates in normal proliferative and neoplastic mouse tissues in vivo. Cancer Res 1981;41:4441-6.
18. Fry DW, Anderson LA, Borst M, Goldman ID. Analysis of the role of membrane transport and polyglutamylation of methotrexate in gut and Ehrlich tumor in vivo as factors in drug sensitivity and selectivity. Cancer Res 1983;43:1087-92.
19. Fabre I, Fabre G, Goldman ID. Polyglutamylation, an important element in methotrexate cytotoxicity and selectivity in tumor versus murine granulocytic progenitor cells in vitro. Cancer Res 1984;44:3190-5.
20. Koizumi S, Curt GA, Fine RL, Griffin JD, Chabner BA. Formation of methotrexate polyglutamates in purified myeloid precursor cells from normal human bone marrow. J Clin Invest 1985;75:1008-14.
21. Allegra CJ, Drake JC, Jolivet J, Chabner BA. Inhibition of phosphoribosylaminoimidazolecarboxamide transformylase by methotrexate and dihydrofolic acid polyglutamates. Proc Natl Acad Sci U S A 1985;82: 4881-5.
22. Allegra CJ, Chabner BA, Drake JC, et al. Enhanced inhibition of thymidylate synthase by methotrexate polyglutamates. J Biol Chem 1985; 260:9720-6.
23. Baggott JE, Vaughn WH, Hudson BB. Inhibition of 5-aminoimidazole4-carboxamide ribotide transformylase, adenosine deaminase and 5′-adenylate deaminase by polyglutamates of methotrexate and oxidized folates and by 5-aminoimidazole-4-carboxamide riboside and ribotide. Biochem J 1986;236:193-200.
24. Chabner BA, Allegra CJ, Curt GA, et al. Polyglutamation of methotrexate. Is methotrexate a prodrug? J Clin Invest 1985;76:907-12.
25. Jones TR, Calvert AH, Jackman AL, et al. A potent antitumour quinazoline inhibitor of thymidylate synthetase: synthesis, biological properties and therapeutic results in mice. Eur J Cancer 1981;17: 11-9.
26. Jackman AL, Taylor GA, Gibson W, et al. ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study. Cancer Res 1991;51:5579-86.
27. Taylor EC, Harrington PJ, Fletcher SR, Beardsley GP, Moran RG. Synthesis of the antileukemic agents 5,10-dideazaaminopterin and 5,10-dideaza-5,6,7,8-tetrahydroaminopterin. J Med Chem 1985;28: 914-21.
28. Beardsley GP, Moroson BA, Taylor EC, Moran RG. A new folate antimetabolite, 5,10-dideaza-5,6,7,8-tetrahydrofolate is a potent inhibitor of de novo purine synthesis. J Biol Chem 1989;264:328-33.
29. Moran RG, Baldwin SW, Taylor EC, Shih C. The 6S- abd 6R-diastereomers of 5,10-dideaza-5,6,7,8-tetrahydrofolate are equiactive inhibitors of de novo purine synthesis. J Biol Chem 1989;264: 21047-51.
30. Baldwin SW, Tse A, Gossett LS, et al. Structural features of 5,10-dideaza-5, 6,7,8-tetrahydrofolate that determine inhibition of mammalian glycinamide ribonucleotide formyltransferase. Biochemistry 1991;30: 1997-2006.
31. Sanghani SP, Moran RG. Tight binding of folate substrates and inhibitors to recombinant mouse glycinamide ribonucleotide formyltransferase. Biochemistry 1997;36:10506-16.
32. Piper JR, McCaleb GS, Montgomery JA, et al. Synthesis and antifolate activity of 5-methyl-5,10-dideaza analogues of aminopterin and folic acid and an alternative synthesis of 5,10-dideazatetrahydrofolic acid, a potent inhibitor of glycinamide ribonucleotide formyltransferase. J Med Chem 1988;31:2164-9.
33. Taylor EC, Hamby JM, Shih C, et al. Synthesis and antitumor activity of 5-deaza-5,6,7,8-tetrahydrofolic acid and its N10-substituted analogues. J Med Chem 1989;32:1517-22.
34. Habeck LL, Leitner TA, Schackelford KA, et al. A novel class of monoglutamated antifolates exhibits tight- binding inhibition of human glycinamide ribonucleotide formyltransferase and potent activity against solid tumors. Cancer Res 1994;54:1021-6.
35. Boritzki TJ, Barlett CA, Zhang C, Howland EF. AG2034: a novel inhibitor of glycinamide ribonucleotide formyltransferase. Invest New Drugs 1996;14:295-303.
36. Desharnais J, Hwang I, Zhang Y, et al. Design, synthesis and biological evaluation of 10-CF3CO-DDACTHF analogues and derivatives as inhibitors of GAR Tfase and the de novo purine biosynthetic pathway. Bioorg Med Chem 2003;11:4511-21.
37. Taylor EC, Kuhnt D, Shih C, et al. A dideazatetrahydrofolate analogue lacking a chiral center at C-6, N-[4-2-(2-amino-3,4-dihydro-4-oxo-7H-pyrrolo[2, 3- d]pyrimidin-5-yl)ethyl]benzoyl]-l-glutamic acid, is an inhibitor of thymidylate synthase. J Med Chem 1992;35:4450-4.
38. Shih C, Chen VJ, Gossett LS, et al. LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res 1997;57:1116-23.
39. Habeck LL, Mendelsohn LG, Shih C, et al. Substrate specificity of mammalian folylpolyglutamate synthetase for 5,10-dideazatetrahydrofolate analogs. Mol Pharmacol 1995;48:326-33.
40. Straw JA, Talbot DC, Taylor GA, Harrap KR. Some observations on the reversibility of methotrexate toxicity in normal proliferating tissues. J Natl Cancer Inst 1977;58:91-7.
41. Pinedo HM, Zaharko DS, Bull JM, Chabner BA. The reversal of methotrexate cytotoxicity to mouse bone marrow cells by leucovorin and nucleosides. Cancer Res 1976;36:4418-24.
42. Hakala MT, Taylor E. The ability of purine and thymine derivatives and of glycine to support the growth of mammalian cells in culture. J Biol Chem 1959;234:126-8.
43. Zhao R, Zhang S, Hanscom M, Chattopadhyay S, Goldman ID. Loss of reduced folate carrier function and folate depletion result in enhanced pemetrexed inhibition of purine synthesis. Clin Cancer Res 2005;11: 1294-301.
44. Zhao R, Gao F, Goldman ID. Marked suppression of the activity of some, but not all, antifolate compounds by augmentation of folate cofactor pools within tumor cells. Biochem Pharmacol 2001;61: 857-65.
45. Andreassi JL, Moran RG. Mouse folylpoly-gamma-glutamate synthetase isoforms respond differently to feedback inhibition by folylpolyglutamate cofactors. Biochemistry 2002;41:226-35.
46. Schultz RM, Patel VF, Worzalla JF, Shih C. Role of thymidylate synthase in the antitumor activity of the multitargeted antifolate, LY231514. Anticancer Res 1999;19:437-43.
47. Zhao R, Goldman ID. Resistance to antifolates. Oncogene 2003;22: 7431-57.
48. Matherly LH, Goldman DI. Membrane transport of folates. Vitam Horm 2003;66:403-56.
49. Sirotnak FM, Kurita S, Hutchison DJ. On the nature of a transport alteration determining resistance to amethopterin in the L1210 leukemia. Cancer Res 1968;28:75-80.
50. Goldman ID, Lichtenstein NS, Oliverio VT. Carrier-mediated transport of the folic acid analogue methotrexate, in the L1210 leukemia cell. J Biol Chem 1968;243:5007-17.
51. Goldman ID. Transport energetics of the folic acid analogue, methotrexate, in L1210 cells: enhanced accumulation by metabolic inhibitors. J Biol Chem 1969;244:3779-85.
52. Goldman ID. The characteristics of the membrane transport of amethopterin and the naturally occurring folates. Ann N Y Acad Sci 1971;186:400-22.
53. Westerhof GR, Schornagel JH, Kathmann I, et al. Carrier- and receptor-mediated transport of folate antagonists targeting folate-dependent enzymes: correlates of molecular-structure and biological activity. Mol Pharmacol 1995;48:459-71.
54. Wang Y, Zhao R, Goldman ID. Characterization of a folate transporter in HeLa cells with a low pH optimum and high affinity for pemetrexed distinct from the reduced folate carrier. Clin Cancer Res 2004;10:6256-64.
55. Mineo C, Anderson RG. Potocytosis. Robert Feulgen Lecture. Histochem Cell Biol 2001;116:109-18.
56. Sierra EE, Brigle KE, Spinella MJ, Goldman ID. Comparison of transport properties of the reduced folate carrier and folate receptor in murine L1210 leukemia cells. Biochem Pharmacol 1995;50:1287-94.
57. Spinella MJ, Brigle KE, Sierra EE, Goldman ID. Distinguishing between folate receptor-α-mediated transport and reduced folate carrier-mediated transport in L1210 leukemia cells. J Biol Chem 1995;270: 7842-9.
58. Dixon KH, Mulligan T, Chung K-N, Elwood PC, Cowan KH. Effects of folate receptor expression following stable transfection into wild type and methotrexate transport-deficient ZR-75- 1 human breast cancer cells. J Biol Chem 1992;267:24140-7.
59. Henderson GB, Tsuji JM, Kumar HP. Mediated uptake of folate by a high-affinity binding protein in sublines of L1210 cells adapted to nanomolar concentrations of folate. J Membr Biol 1988;101:247-58.
60. Theti DS, Bavetsias V, Skelton LA, et al. Selective delivery of CB300638, a cyclopenta[g]quinazoline-based thymidylate synthase inhibitor into human tumor cell lines overexpressing the alpha-isoform of the folate receptor. Cancer Res 2003;63:3612-8.
61. Wu M, Gunning W, Ratnam M. Expression of folate receptor type alpha in relation to cell type, malignancy, and differentiation in ovary, uterus, and cervix. Cancer Epidemiol Biomarkers Prev 1999;8:775-82.
62. Mantovani LT, Miotti S, Ménard S, et al. Folate binding protein distribution in normal tissues and biological fluids from ovarian carcinoma patients as detected by the monoclonal antibodies MOv18 and MOv19. Eur J Cancer [A] 1994;30A:363-9.
63. Toffoli G, Cernigoi C, Russo A, et al. Overexpression of folate binding protein in ovarian cancers. Int J Cancer 1997;74:193-8.
64. Strum WB. Enzymatic reduction and methylation of folate following pH-dependent, carrier-mediated transport in rat jejunum. Biochim Biophys Acta 1979;554:249-57.
65. Said HM, Strum WB. A pH-dependent, carrier-mediated system for transport of 5-methyltetrahydrofolate in rat jejunum. J Pharmacol Exp Ther 1983;226:95-9.
66. Selhub J, Rosenberg IH. Folate transport in isolated brush border membrane vesicles from rat intestine. J Biol Chem 1981;256:4489-93.
67. Schron CM, Washington C, Jr., Blitzer BL. The transmembrane pH gradient drives uphill folate transport in rabbit jejunum. Direct evidence for folate/hydroxyl exchange in brush border membrane vesicles. J Clin Invest 1985;76:2030-3.
68. Said HM, Ma TY, Ortiz A, Tapia A, Valerio CK. Intracellular regulation of intestinal folate uptake: studies with cultured IEC-6 epithelial cells. Am J Physiol Cell Physiol 1997;272:C729-36.
69. Rajgopal A, Sierra EE, Zhao R, Goldman ID. Expression of the reduced folate carrier SLC19A1 in IEC-6 cells results in two distinct transport activities. Am J Physiol Cell Physiol 2001;281:C1579-86.
70. Vincent ML, Russell RM, Sasak V. Folic acid uptake characteristics of a human colon carcinoma cell line, Caco-2. A newly-described cellular model for small intestinal epithelium. Hum Nutr Clin Nutr 1985; 39:355-60.
71. Zhao R, Gao F, Hanscom M, Goldman ID. A prominent low-pH methotrexate transport activity in human solid tumor cells: contribution to the preservation of methotrexate pharmacological activity in HeLa cells lacking the reduced folate carrier. Clin Cancer Res 2004; 10:718-27.
72. Zhao R, Hanscom M, Goldman ID. The relationship between folate transport activity at low pH and reduced folate carrier function in human Huh7 hepatoma cells. Biochim Biophys Acta 2005;1715: 57-64.
73. Chattopadhyay S, Zhao R, Krupenko SA, Krupenko N, Goldman ID. The inverse relationship between reduced folate carrier function and pemetrexed activity in a human colon cancer cell line. Mol Cancer Ther 2006;5:438-49.
74. Wang Y, Rajgopal A, Goldman ID, Zhao R. Preservation of folate transport activity with a low-pH optimum in rat IEC-6 intestinal epithelial cell lines that lack reduced folate carrier function. Am J Physiol Cell Physiol 2005;288:C65-71.
75. Qiu A, Jansen M, Sakaris A, et al. Identification of an intestinal folate transporter and the molecular basis for hereditary folate malabsorption. Cell 2006;127:917-28.
76. Zhao R, Hanscom M, Chattopadhyay S, Goldman ID. Selective preservation of pemetrexed pharmacological activity in HeLa cells lacking the reduced folate carrier; association with the presence of a secondary transport pathway. Cancer Res 2004;64:3313-9.
77. Zhao R, Chattopadhyay S, Hanscom M, Goldman ID. Antifolate resistance in a HeLa cell line associated with impaired transport independent of the reduced folate carrier. Clin Cancer Res 2005;10: 8735-42.
78. Hagenbuch B, Meier PJ. The superfamily of organic anion transporting polypeptides. Biochim Biophys Acta 2003;1609:1-18.
79. Kruh GD, Belinsky MG. The MRP family of drug efflux pumps. Oncogene 2003;22:7537-52.
80. Volk EL, Schneider E. Wild-type breast cancer resistance protein (BCRP/ ABCG2) is a methotrexate polyglutamate transporter. Cancer Res 2003;63:5538-43.
81. Zhao R, Babani S, Gao F, Liu L, Goldman ID. The mechanism of transport of the multitargeted antifolate, MTA-LY231514, and its cross resistance pattern in cell with impaired transport of methotrexate. Clin Cancer Res 2000;6:3687-95.
82. Halsted CH, Ling EH, Luthi-Carter R, et al. Folylpoly-gammaglutamate carboxypeptidase from pig jejunum. Molecular characterization and relation to glutamate carboxypeptidase II. J Biol Chem 1998;273: 20417-24.
83. Cole PD, Kamen BA, Gorlick R, et al. Effects of overexpression of gamma-Glutamyl hydrolase on methotrexate metabolism and resistance. Cancer Res 2001;61:4599-604.
84. Whitehead VM, Kalman TI, Vuchich MJ. Inhibition of gammaglutamyl hydrolases in human cells by 2-mercaptomethylglutaric acid. Biochem Biophys Res Commun 1987;144:292-7.
85. Rhee MS, Wang Y, Nair MG, Galivan J. Acquisition of resistance to antifolates caused by enhanced gamma-glutamyl hydrolase activity. Cancer Res 1993;53:2227-30.
86. Schneider E, Ryan TJ. Gamma-glutamyl hydrolase and drug resistance. Clin Chim Acta. Epub 2006.
87. Chattopadhyay S, Wang Y, Zhao R, Goldman ID. Lack of impact of the loss of constitutive folate receptor alpha expression, achieved by RNA Interference, on the activity of the new generation antifolate pemetrexed in HeLa cells. Clin Cancer Res 2004;10:7986-93.
88. Parker N, Turk MJ, Westrick E, et al. Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Anal Biochem 2005;338:284-93.
89. Matherly LH, Barlowe CK, Phillips VM, Goldman ID. The effects on 4-aminoantifolates on 5-formyltetrahydrofolate metabolism in L1210 cells. A biochemical basis of the selectivity of leucovorin rescue. J Biol Chem 1987;262:710-7.
90. Chen VJ, Bewley JR, Andis SL, et al. Preclinical cellular pharmacology of LY231514 (MTA): a comparison with methotrexate. LY309887 and raltitrexed for their effects on intracellular folate and nucleoside triphosphate pools in CCRF-CEM cells. Br J Cancer 1998;78 Suppl 3:27-34.
91. Moran RG, Mulkins M, Heidelberger C. Role of thymidylate synthetase activity in development of methotrexate cytotoxicity. Proc Natl Acad Sci U S A 1979;76:5924-8.
92. Zhao R, Titus S, Gao F, Moran RG, Goldman ID. Molecular analysis of murine leukemia cell lines resistant to 5,10- ideazatetrahydrofolate identifies several amino acids critical to the function of folylpolyglutamate synthetase. J Biol Chem 2000;275:26599-606.
93. Liani E, Rothem L, Bunni MA, et al. Loss of folylpoly-gammaglutamate synthetase activity is a dominant mechanism of resistance to polyglutamylation-dependent novel antifolates in multiple human leukemia sublines. Int J Cancer 2003;103:587-99.
94. Schultz RM, Chen VJ, Bewley JR, et al. Biological activity of the multitargeted antifolate, MTA (LY231514), in human cell lines with different resistance mechanisms to antifolate drugs. Semin Oncol 1999; 26 Suppl 6:68-73.
95. Jackman AL, Kelland LR, Kimbell R, et al. Mechanisms of acquired resistance to the quinazoline thymidylate synthase inhibitor ZD1694 (Tomudex) in one mouse and three human cell lines. Br J Cancer 1995;71: 914-24.
96. Backus HH, Pinedo HM, Wouters D, et al. Folate depletion increases sensitivity of solid tumor cell lines to 5- fluorouracil and antifolates. Int J Cancer 2000;87:771-8.
97. Clarke SJ, Hanwell J, de Boer M, et al. Phase I trial of ZD1694, a new folate-based thymidylate synthase inhibitor, in patients with solid tumors. J Clin Oncol 1996;14:1495-503.
98. Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 2003;3:330-8.
99. Jackson RC, Jackman AL, Calvert AH. Biochemical effects of a quinazoline inhibitor of thymidylate synthetase, N-(4-(N-((2-amino-4-hydroxy-6-quinazolinyl)methyl)prop-2-ynylamino) benzoyl)-l-glutamic acid (CB3717), on human lymphoblastoid cells. Biochem Pharmacol 1983;32: 3783-90.
100. Piall EM, Curtin NJ, Aherne GW, Harris AL, Marks V. The quantitation by radioimmunoassay of 2'-deoxyuridine 5'-triphosphate in extracts of thymidylate synthase-inhibited cells. Anal Biochem 1989;l77: 347-52.
101. Mitrovski B, Pressacco J, Mandelbaum S, Erlichman C. Biochemical effects of folate-based inhibitors of thymidylate synthase in MGH-U1 cells. Cancer Chemother Pharmacol 1994;35:109-14.
102. Myers CE, Young RC, Chabner BA. Biochemical determinants of 5-fluorouracil response in vivo. The role of deoxyuridylate pool expansion. J Clin Invest 1975;56:1231-8.
103. Myers CE, Young RC, Johns DG, Chabner BA. Assay of 5-fluorodeoxyuridine 5'-monophosphate deoxyuridine 5'-monophosphate pools following 5-fluorouracil. Cancer Res 1974;34:2682-8.
104. Moran RG, Spears CP, Heidelberger C. Biochemical determinants of tumor sensitivity to 5-fluorouracil: ultrasensitive methods for the determination of 5-fluoro-2'-deoxyuridylate, 2'-deoxyuridylate, and thymidylate synthetase. Proc Natl Acad Sci U S A 1979;76:1456-60.
105. Galivan JH, Maley F, Baugh CM. Demonstration of separate binding sites for the folate coenzymes and deoxynucleotides with inactivated Lactobacillus casei thymidylate synthetase. Biochem Biophys Res Commun 1976;71:527-34.
106. Carreras CW, Santi DV. The catalytic mechanism and structure of thymidylate synthase. Annu Rev Biochem 1995;64:721-62.
107. Keyomarsi K, Moran RG. Mechanism of the cytotoxic synergism of fluoropyrimidines and folinic acid in mouse leukemic cells. J Biol Chem 1988;263:14402-9.
108. Rinaldi DA, Burris HA, Dorr FA, et al. Initial phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, using the modified continual reassessment method for dose escalation. J Clin Oncol 1995; 13:2842-50.
109. McDonald AC, Vasey PA, Adams L, et al. A phase I and pharmacokinetic study of LY231514, the multitargeted antifolate. Clin Cancer Res 1998;4:605-10.
110. Rinaldi DA, Kuhn JG, Burris HA, et al. A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation. Cancer Chemother Pharmacol 1999;44:372-80.
111. Rinaldi DA. Overview of phase I trials of multitargeted antifolate (MTA, LY231514). Semin Oncol 1999;26 suppl 6:82-8.
112. Mita AC, Sweeney CJ, Baker SD, et al. Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function. J Clin Oncol 2006;24: 552-62.
113. Frenia ML, Long KS. Methotrexate and nonsteroidal antiinflammatory drug interactions. Ann Pharmacother 1992;26:234-7.
114. Sweeney CJ, Takimoto CH, Latz JE, et al. Two drug interaction studies evaluating the pharmacokinetics and toxicity of pemetrexed when coadministered with aspirin or ibuprofen in patients with advanced cancer. Clin Cancer Res 2006;12:536-42.
115. Thodtmann R, Depenbrock H, Dumez H, at al. Clinical and pharmacokinetic phase I study of multitargeted antifolate (LY231514) in combination with cisplatin. J Clin Oncol 1999;17:3009-16.
116. Hughes A, Calvert P, Azzabi A, et al. Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma. J Clin Oncol 2002;20:3533-44.
117. Fizazi K, John WJ, Vogelzang NJ. The emerging role of antifolates in the treatment of malignant pleural mesothelioma. Semin Oncol 2002;29: 77-81.
118. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21: 2636-44.
119. Niyikiza C, Baker SD, Seitz DE, et al. Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy. Mol Cancer Ther 2002;1:545-52.
120. Bunn P, Paoletti P, Niyikiza C, et al. Vitamin B12 and folate reduce toxicity of ALIMTA (pemetrexed disodium, LY231514, MTA), a novel antifolate/antimetabolite [abstr 300]. Proc Am Soc Clin Oncol 2001; 20:76a.
121. Gralla RJ, Hollen PJ, Liepa AM, et al. Improving quality of life in patients with malignant pleural mesothelioma: results of the randomized pemetrexed + cisplatin vs. cisplatin trial using the LCSS-meso instrument [abstract 2946]. Proc Am Soc Clin Oncol 2003;22:621.
122. Paoletti P, Pistolesi M, Rusthoven JJ, et al. Correlation of pulmonary function tests with best tumor response status: results from the phase III study of pemetrexed + cisplatin vs. cisplatin in malignant pleural mesothelioma [abstract 2651]. Proc Am Soc Clin Oncol 2003;22:659.
123. Hazarika M, White RM, Johnson JR, Pazdur R. FDA drug approval summaries: pemetrexed (Alimta). Oncologist 2004;9:482-8.
124. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22:1589-97.
125. Fossella F, Obasaju C, Paul S. Pemetrexed vs docetaxel for non-small cell lung cancer (NSCLC): could vitamin supplementation affect docetaxel survival? [abstract 7131]. An exploratory analysis. J Clin Oncol 2004;22 (July 15 Suppl):649S.
126. Cohen MH, Johnson JR, Wang YC, Sridhara R, Pazdur R. FDA drug approval summary: pemetrexed for injection (Alimta) for the treatment of non-small cell lung cancer. Oncologist 2005;10:363-8.
127. Adjei AA. Pemetrexed (ALIMTA), a novel multitargeted antineoplastic agent. Clin Cancer Res 2004;10:4276-80S.
128. Tonkinson JL, Worzalla JF, Tang CH, Mendelsohn LG. Cell cycle modulation by a multitargeted antifolate, LY231514, increases the cytotoxicity and antitumor activity of gemcitabine in HT29 colon carcinoma. Cancer Res 1999;59:3671-6.
129. Giovannetti E, Mey V, Danesi R, Mosca I, Del Tacca M. Synergistic cytotoxicity and pharmacogenetics of gemcitabine and pemetrexed combination in pancreatic cancer cell lines. Clin Cancer Res 2004;10: 2936-43.
130. Giovannetti E, May V, Nannizzi S, et al. Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non-small-cell lung cancer cells. Mol Pharmacol 2005;68: 110-8.
131. Oettle H, Richards D, Ramanathan RK, et al. A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. Ann Oncol 2005;16: 1639-45.
132. Me CX, Nair S, Thomas S, et al. Randomized phase II trial of three schedules of pemetrexed and gemcitabine as front-line therapy for advanced non-small-cell lung cancer. J Clin Oncol 2005;23:5929-37.
133. Scagliotti GV, Shin DM, Kindler HL, et al. Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma. J Clin Oncol 2003;21: 1556-61
134. Homocysteine Lowering Trialists' Collaboration. Dose-dependent effects of folic acid on blood concentrations of homocysteine: a meta-analysis of the randomized trials. Am J Clin Nutr 2005;82:806-12.
135. Wald NJ, Law MR, Morris JK, Wald DS. Quantifying the effect of folic acid. Lancet 2001;358:2069-73.
136. Eli Lilly and Company. Alimta product information. Physicians' desk reference. 59th ad. Montvale (NJ): Thomson PDR; 2005. p. 1824-8.
137. Sanghani PC, Moran RG. Purification and characteristics of recombinant human folylpoly-gamma-glutamate synthetase expressed at high levels in insect cells. Protein Expr Purif 2000;18:36-45.